GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Oncotelic Therapeutics Inc. (OTC:OTLC), the RNA-based therapeutics company, says it is making progress advancing its antisense oligonucleotide (ASO) platform, fueled by promising clinical data and ...

(RTTNews) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) ...

SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, today noted important new guidance recently issued by the U.S. Food and Drug Administration (FDA) regarding both the manufacturing ...

-Five scientific posters to be presented at upcoming EASL ILC meeting- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being ...

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and ...

SAN DIEGO--(BUSINESS WIRE)--The editors of Nature Biotechnology recently published an editorial entitled “Ultra-precision medicine” in the June 2021 issue of Nature Biotechnology i, highlighting new ...